PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of nihpaAbout Author manuscriptsSubmit a manuscriptHHS Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
 
Mol Genet Metab. Author manuscript; available in PMC 2010 April 1.
Published in final edited form as:
PMCID: PMC2676341
NIHMSID: NIHMS106006

EXOGENOUS MANNOSE DOES NOT RAISE STEADY STATE MANNOSE-6-PHOSPHATE POOLS OF NORMAL OR N-GLYCOSYLATION-DEFICIENT HUMAN FIBROBLASTS

Abstract

Increasing intracellular mannose-6-phosphate (Man-6-P) was previously reported to reduce the amount of the major lipid linked oligosaccharide (LLO) precursor of N-glycans; a loss that might decrease cellular N-glycosylation. If so, providing dietary mannose supplements to glycosylation-deficient patients might further impair their glycosylation. To address this question, we studied the effects of exogenous mannose on intracellular levels of Man-6-P, LLO, and N-glycosylation in human and mouse fibroblasts. Mannose (500μM) did not increase Man-6-P pools in human fibroblasts from controls or from patients with Congenital Disorders of Glycosylation (CDG), who have 90–95% deficiencies in either phosphomannomutase (CDG-Ia) or phosphomannose isomerase (MPI) (CDG-Ib), enzymes that both use Man-6-P as a substrate. In the extreme case of fibroblasts derived from Mpi null mice (<0.001% MPI activity), intracellular Man-6-P levels greatly increased in response to exogenous mannose, and this produced a dose-dependent decrease in the steady state level of the major LLO precursor. However, LLO loss did not decrease total protein N-glycosylation or that of a hypoglycosylation indicator protein, DNaseI. These results make it very unlikely that exogenous mannose could impair N-glycosylation in glycosylation-deficient CDG patients.

INTRODUCTION

Mannose-6-P (Man-6-P) is a precursor for N-glycan synthesis. Man-6-P is converted to Man-1-P, then to GDP-Man and dolichol-P-Man for synthesis of the universal lipid linked oligosaccharide (LLO) donors of N-glycans. (See Scheme 1) (Eklund, et al. 2007). Two pathways can generate Man-6-P: phosphorylation of mannose via hexokinase or conversion of fructose-6-P via phosphomannose isomerase (MPI) (Eklund, et al. 2007). Both pathways contribute mannose to N-glycosylation. Patients with congenital disorder of glycosylation (CDG) Type Ib have an 85–95% deficiency in MPI activity (Eklund and Freeze 2006, Freeze 2006), resulting in unoccupied N-glycosylation sites in many proteins. Dietary supplements of mannose correct the patients’ abnormal glycosylation and pathological features (Eklund and Freeze 2006, Freeze 2006). In mice, ablation of Mpi is lethal by embryonic day 10.5 due to intracellular accumulation of toxic levels of Man-6-P that can reach 25mM (DeRossi, et al. 2006).

LLO and protein synthesis are coordinated, but LLO is likely in excess since intact LLO glycan is also hydrolyzed from the lipid carrier (Lehrman 2006, Moore and Spiro 1994, Spiro and Spiro 1991). Recently, an in vitro study using streptolysin-O-permeabilized cells showed that modest concentrations of Man-6-P (10–100μM) specifically decreased the predominant LLO species, Glc3Man9GlcNAc2-PP-Dol (Gao, et al. 2005), generating the free intact glycan. Decreasing LLO might also decrease protein N-glycosylation. Since previous studies suggested that the intracellular concentration of Man-6-P in rat liver was ~100μM (Asikin and Koeppe 1979), even slight increases might decrease LLO and limit N-glycosylation (Gao, et al. 2005).

Under this scenario, providing mannose to phosphomannomutase- (PMM2, Man- 6P→Man-1-P) deficient CDG-Ia patients, who already have reduced N-glycosylation, might further compromise their glycosylation by increasing intracellular Man-6-P. Although mannose therapy in CDG-Ia patients showed no benefit, it did not appear to further decrease glycosylation of plasma glycoproteins (Kjaergaard, et al. 1998, Mayatepek and Kohlmüller 1998, Mayatepek, et al. 1997).

We asked whether exogenous mannose increases Man-6-P in fibroblasts from control subjects or from CDG-Ia or CDG-Ib patients. Our results showed no detectable increase, making it unlikely that mannose would decrease glycosylation in patients. To test the extreme case, we also asked whether exogenous mannose would decrease LLO levels in mouse Mpi−/− fibroblasts that accumulate extremely high levels of Man-6-P in response to exogenous mannose. We found that Mpi−/− cells accumulated Man-6-P and specifically lost a portion of their Glc3Man9GlcNAc2-PP-Dol, but this loss does not affect overall N- glycosylation or that of a sensitive hypoglycosylation marker protein, DNaseI (Eklund, et al. 2005, Fujita, et al. 2008).

MATERIALS AND METHODS

Human and Mouse Fibroblasts

Human control fibroblasts were obtained from Advanced Tissue Science or Coriell Cell Repository. Fibroblasts from patients were obtained from physicians as part of their CDG diagnostic workup following informed consent approval from parents or guardians.

Mannose-6-P analysis

Cells were incubated in DMEM medium with 5.5mM glucose and 20% fetal bovine serum with the indicated amount of mannose for 8 hrs before analysis. In some cases, serum was dialyzed to remove endogenous mannose prior to use. The extraction, HPLC analysis, and quantitation of Man-6-P was done as previously described (DeRossi, et al. 2006).

DNaseI and Protein Glycosylation Analysis

DNaseI construct, infection protocols and analysis of its glycosylation status were described previously (Eklund, et al. 2005, Fujita, et al. 2008). To determine protein glycosylation, mouse fibroblasts in the presence or absence of mannose were labeled with 35S-amino acids for 4hr. Labeled proteins in the medium were bound to ConcanavalinA and eluted with 100 mM α-methyl mannoside. The resulting material was analyzed by reducing SDS-PAGE and visualized by flourography as described for analysis of DNaseI.

Analysis of LLOs

Cells were grown in DMEM medium with 20% FBS and the indicated amount of mannose. Approximately 1.0 × 107 cells were suspended in methanol and dried under a stream of dry N2. LLOs were extracted as previously described (Gao and Lehrman, 2002) using chloroform–methanol–water (CMW; 10:10:3). Intact glycan chains were liberated from LLO by mild acid hydrolysis and then loaded onto C18 SepPak column directly connected to 3 ml ENVI-CARB solid phase extraction tube to remove residual salt and lipids (Gruberman et al, 2004). After loading, columns were washed with 9 ml of 2% acetonitrile/0.1 M ammonium acetate in H2O and the glycans eluted from the ENVI-CARB with 6 ml of H2O-acetonitrile (3:1, v/v), dried and labeled with 2-aminopyridine for HPLC analysis.

RESULTS

Effects of exogenous mannose on intracellular Man-6-P in human and mouse fibroblasts

We analyzed fibroblasts from normal controls and from three different types of CDG patients, who exhibit protein hypoglycosyaltion. Cells were grown in medium containing physiological glucose (5.5mM) and 0 or 500 μM mannose for 24 hours and intracellular amount of Man-6-P was determined. PMM2-deficient CDG-Ia, cells and MPI-deficient, CDG-Ib cells have defects which could increase the intracellular level of Man-6-P. ALG6-deficient cells from CDG-Ic patients have a defect in LLO biosynthesis and would not be expected to show any change in Man-6-P levels. (Freeze 2006). There was no detectable increase in Man-6-P in any of the human cell lines in response to mannose. Representative data are shown in Figure 1.

Figure 1
Effects of exogenous mannose on intracellular Man-6-P. Human control, CDG-Ia (PMM2 deficient), CDG-Ib (MPI-deficient), CDG-Ic (ALG6-deficient) and mouse fibroblasts from Mpi+/+ and Mpi−/− embryos were incubated with medium containing 10% ...

We next studied fibroblasts derived from wild-type Mpi+/+ mice. They also did not have detectable intracellular Man-6-P (<0.5nmole/100μg protein), but addition of 500μM mannose to the medium increases the level to 1.3 nmole/100ug protein. However, fibroblasts derived from Mpi−/− cells (< 0.001% normal MPI activity) and grown in 10% serum with 5μM mannose accumulated detectable Man-6-P (1.2nmole/100μg protein); addition of 500 μM mannose to the medium further increased that level ~10-fold (10nmole/100μg protein), similar to that seen in previous studies of Mpi−/− mouse fibroblasts (DeRossi, et al. 2006).

Effects of exogenous mannose on LLO levels in Mpi−/− cells

Mpi−/− fibroblasts require mannose for survival and must either import exogenous mannose and/or salvage it from degraded glycans (DeRossi, et al. 2006). Mpi−/− cells can grow normally in 100% serum, showing that they salvage sufficient mannose from serum glycoproteins. If the salvage pathway is blocked, adding 10–15 μM free exogenous mannose restores normal glycosylation (Fujita, et al. 2008). A combination of 100μM mannose and 10–20% serum is cytostatic over several days, and 500μM mannose becomes cytotoxic beyond 24 hr due to the accumulation of Man-6-P (DeRossi, et al. 2006).

Previous in vitro studies using streptolysin-O permeabilized mammalian cells showed that Man-6-P selectively reduced the amount of LLO available for glycosylation (Gao, et al. 2005). By using intact Mpi−/− cells, we could manipulate Man-6-P levels with exogenous mannose and then determine effects on the steady-state amount of Glc3Man9GlcNAc2PP-Dol and other LLO species (DeRossi, et al. 2006). Representative elution profiles (Figure 2) and quantitation from several experiments (Table 1) show the amount of the predominant LLO species. Wild-type mouse cells made nearly the same amount and spectrum of LLO species regardless of the addition of exogenous mannose. (Figure 2, A and B and Table 1, experiments 1 and 2). Mpi−/− cells grown in dialyzed 10% serum with 100 μM mannose made a smaller amount of Glc3Man9GlcNAc2PP-Dol and higher amount of Man9GlcNAc2PP-Dol than controls under similar conditions (Figure 2, C and Table 1, experiment 1). In 500μM mannose, Mpi−/− cells maintained about the same amount of Man9GlcNAc2PP-Dol, but specifically decreased the amount of Glc3Man9GlcNAc2PP-Dol (Figure 2, D). Without addition of mannose to Mpi−/− cells, 20% serum was insufficient to generate a normal amount of LLO seen in control cells (Experiments 3 and 4, Table 1); however, the size distribution was similar to that seen in control cells (Figure 2, E). Adding mannose at 20μM nearly normalized the amount of LLO (Table 1, experiments 2, 3 and 4), but providing 100μM mannose reduced the steady state amount Glc3Man9GlcNAc2-PP-Dol, and consistently increased Man9GlcNAc2-PP- Dol (Table 1). Adding 500μM mannose reduced the total amount of LLO in Mpi−/− cells, and especially decreased Glc3Man9GlcNAc2-PP-Dol. Taken together, results using intact Mpi−/− cells confirm previous in vitro studies showing Man-6-P- dependent depletion of steady state Glc3Man9GlcNAc2-PP-Dol (Gao, et al. 2005).

Figure 2Figure 2
LLO profiles in Normal and Mpi−/− fibroblasts in response to mannose. Cells were incubated in the presence of the indicted amount of mannose in medium containing 5.5 mM glucose and 20% FBS for 24 hours and LLO glycans prepared and analyzed ...
Table 1
Amount of LLO (pmol/107 cell)

Increased Man-6-P and decreased Glc3Man9GlcNAc2PP-Dol does not reduce N-glycosylation

We wanted to know if the reduced amount of Glc3Man9GlcNAc2-PP-Dol also reduced N-glycosylation in the Mpi−/− cells. An engineered form of DNaseI containing a single N-glycosylation site is a sensitive indicator of insufficient glycosylation because the consensus sequon, -NDS-, is poorly glycosylated (Eklund, et al. 2005, Fujita, et al. 2008). If LLO is limiting or an incomplete LLO glycan species is inefficiently transferred, DNaseI should show hypo-N-glycosyaltion, i.e., unoccupied N-glycosylation sites, as it does in CDG-Ia, -Ib and –Ic cells (Freeze 2006) and in Mpi−/− fibroblasts without exogenous mannose or mannose salvage pathway (Fujita, et al. 2008). Mouse cells were transfected with an adenovirus construct harboring DNaseI, and then incubated with increasing amounts of mannose to increase intracellular Man-6-P. Cells were labeled with 35S-amino acids, secreted DNaseI isolated from the medium, and glycosylated and non-glycosylated forms resolved by SDS-PAGE. As shown previously, the upper band is N-glycosylated, while the lower band is not, based on digestion with PNGaseF (data not shown). Results in Figure 3a show that even though the steady state level of Glc3Man9GlcNAc2PP-Dol decreased in response to increased Man-6-P, the amount of DNaseI and its degree of N- glycosylation was unaffected, remaining at 75–77%. Likewise, overall protein glycosylation as measured by binding of 35S amino acid-labeled proteins to Concanavalin A, also remained normal (Figure 3b). These results show that even though exogenous mannose greatly increased intracellular Man-6-P and decreased the steady state level of the major LLO, it did not alter the extent of protein N-glycosylation.

Figure 3
Effects of mannose on N-glycosylation of DNaseI and total secreted proteins. Mpi−/− fibroblasts were incubated in medium containing the indicated concentration of mannose and for 4 h and labeled with 35S-amino acids. Panel A. DNaseI was ...

DISCUSSION

Metabolic disorders caused by mutations in linear biosynthetic pathways often accumulate substrate proximal to the lesion and decrease the amount of product distal to it. This approach was used to identify many types of CDG, based on the synthesis of incomplete LLO glycan chains (Freeze 2006). So, it was reasonable to predict that PMM2-deficient CDG-Ia cells (and possibly patients themselves) might accumulate Man-6-P. Addition of exogenous mannose might further increase this amount since these cells would not efficiently convert Man-6-P into Man-1-P (Gao, et al. 2005). Accumulation of Man-6-P might further exacerbate the patients’ impaired N-glycosylation by cleaving the predominant LLO species (Gao, et al. 2005). This perspective would argue that giving these patients mannose might actually be harmful. However, this is not necessarily true since PMM2-deficient CDG-Ia patients have normal MPI activity, and they could still catabolize Man-6-P. Similarly, providing hyper-physiological levels of mannose to MPI-deficient fibroblasts or patients might also cause accumulation of Man-6-P. However, our results show that exogenous mannose did not detectably increase Man-6-P in patient cell lines. The simplest interpretation of these results is that both groups of patients have sufficient MPI activity to catabolize excess Man-6-P and prevent its accumulation. Previous results showing that dietary supplements of mannose neither improve nor decrease N-glycosylation when given to CDG-Ia patients (Kjaergaard, et al. 1998, Mayatepek and Kohlmüller 1998, Mayatepek, et al. 1997), but mannose rescues deficient glycosylation in partially MPI-deficient, CDG-Ib, patients (Niehues, et al. 1998) by overcoming their Man-6-P deficiency. Taken together, these results make it very unlikely that providing mannose supplements to CDG-Ia patients would increase Man-6-P and further inhibit protein glycosylation.

In contrast to patients with hypomorphic alleles, Mpi−/− mouse fibroblasts have no (<0.001%) residual enzymatic activity and, therefore, accumulate Man-6-P (DeRossi, et al. 2006) because its entry into glycolysis is blocked. We confirmed the in vitro finding (Gao, et al. 2005) that a dose-dependent increase of Man-6-P decreases Glc3Man9GlcNAc2PP-Dol levels, but the loss occurs at very high levels of Man-6-P that can only be achieved in cells lacking all Mpi enzymatic activity. Adding 500μM mannose to Mpi+/+ control mouse fibroblasts slightly increases intracellular Man-6-P. Surprisingly, the decreased steady state amount of Glc3Man9GlcNAc2PP-Dol LLO seen in Mpi−/− cells exposed to 500μM mannose did not reduce N-glycosylation of DNaseI or of total proteins as measured by binding of metabolically labeled proteins to Concanavalin A. This observation shows that LLO glycan is transferred to proteins at normal efficiency, and further suggests that the steady state LLO pool is in excess, at least in these cells. The decreased steady state level of Glc3Man9GlcNAc2PP-Dol seen in mannose-supplemented cells may simply reflect the excess remaining after Glc3Man9GlcNAc2, was transferred to protein.

Currently, there is no explanation for how elevating Man-6-P in the cytoplasm specifically cleaves the glycan moiety of Glc3Man9GlcNAc2PP-Dol on the luminal side of the endoplasmic reticulum. Man-6-P is formed in the cytoplasm and is unlikely to enter the ER lumen. If this molecule acts as a metabolic sensor to coordinate glycosylation site occupancy in response to stress, it may be a transmembrane signaling event tied to the rate of protein synthesis (Lehrman 2006, Shang, et al. 2007). Since Man-6-P links glycosylation and glucose metabolism, it is appropriately located to serve as a metabolic sensor. Very high concentrations of Man-6-P inhibit phosphoglucose isomerase and glucose-6-P dehydrogenase (DeRossi, et al. 2006) and so excessive and uncontrolled accumulation of Man-6-P may be undesirable.

Whether modest increases in Man-6-P concentration in the physiological range can control Glc3Man9GlcNAc2PP-Dol level is not proven, but our data show no effect on total protein N-glycosylation or of a sensitive marker for glycosylation site occupancy.

Acknowledgments

This work was supported by grant R01 DK55615 to HF and postdoctoral fellowship from the Deutsche Forshungsgemeinschaft (DFG, BO2488/1-1) to LB.

Footnotes

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

References

  • Asikin N, Koeppe RE. Mannos-6-P and mannose-1-P in rat brain, kidney and liver. Biochem Biophys Res Commun. 1979;89:279–285. [PubMed]
  • DeRossi C, Bode L, Eklund EA, Zhang F, Davis JA, Westphal V, Wang L, Borowsky AD, Freeze HH. Ablation of mouse phosphomannose isomerase (Mpi) causes mannose 6-phosphate accumulation, toxicity, and embryonic lethality. Journal of Biological Chemistry. 2006;281:5916–5927. [PubMed]
  • Eklund E, Bode L, Freeze H. Diseases Associated with Carbohydrates/Glycoconjugates. In: Kamerling J, editor. Comprehensive Glycoscience. 419. Vol. 4. Elsevier; Oxford: 2007. pp. 339–372.
  • Eklund EA, Freeze HH. The congenital disorders of glycosylation: a multifaceted group of syndromes. NeuroRx. 2006;3:254–263. [PubMed]
  • Eklund EA, Merbouh N, Ichikawa M, Nishikawa A, Clima JM, Dorman JA, Norberg T, Freeze HH. Hydrophobic Man-1-P derivatives correct abnormal glycosylation in Type I congenital disorder of glycosylation fibroblasts. Glycobiology. 2005;15:1084–1093. [PubMed]
  • Freeze HH. Genetic defects in the human glycome.[erratum appears in Nat Rev Genet. 2006 Aug;7(8):660] Nature Reviews Genetics. 2006;7:537–551. [PubMed]
  • Fujita N, Tamura A, Higashidani A, Tonozuka T, Freeze HH, Nishikawa A. The relative contribution of mannose salvage pathways to glycosylation in PMI-deficient mouse embryonic fibroblast cells. Febs J. 2008;275:788–798. [PubMed]
  • Gao N, Shang J, Lehrman MA. Analysis of glycosylation in CDG-Ia fibroblasts by fluorophore-assisted carbohydrate electrophoresis: implications for extracellular glucose and intracellular mannose 6-phosphate. J Biol Chem. 2005;280:17901–17909. [PMC free article] [PubMed]
  • Kjaergaard S, Kristiansson B, Stibler H, Freeze HH, Schwartz M, Martinsson T, Skovby F. Failure of short-term mannose therapy of patients with carbohydrate-deficient glycoprotein syndrome type 1A. Acta Paediatr. 1998;87:884–888. [PubMed]
  • Lehrman MA. Stimulation of N-linked glycosylation and lipid-linked oligosaccharide synthesis by stress responses in metazoan cells. Crit Rev Biochem Mol Biol. 2006;41:51–75. [PubMed]
  • Mayatepek E, Kohlmüller D. Mannose supplementation in carbohydrate-deficient glycoprotein syndrome type I and phosphomannomutase deficiency. Eur J Pediatr. 1998;157:605–606. [PubMed]
  • Mayatepek E, Schröder M, Kohlmuller D, Bieger WP, Nutzenadel W. Continuous mannose infusion in carbohydrate-deficient glycoprotein syndrome type I. Acta Paediatr. 1997;86:1138–1140. [PubMed]
  • Moore SE, Spiro RG. Intracellular compartmentalization and degradation of free polymannose oligosaccharides released during glycoprotein biosynthesis. J Biol Chem. 1994;269:12715–12721. [PubMed]
  • Niehues R, Hasilik M, Alton G, Körner C, Schiebe-Sukumar M, Koch HG, Zimmer KP, Wu R, Harms E, Reiter K, von Figura K, Freeze HH, Harms HK, Marquardt T. Carbohydrate-deficient glycoprotein syndrome type Ib. Phosphomannose isomerase deficiency and mannose therapy. J Clin Invest. 1998;101:1414–1420. [PMC free article] [PubMed]
  • Shang J, Gao N, Kaufman RJ, Ron D, Harding HP, Lehrman MA. Translation attenuation by PERK balances ER glycoprotein synthesis with lipid linked oligosaccharide flux. J Cell Biol. 2007;176:605–616. [PMC free article] [PubMed]
  • Spiro MJ, Spiro RG. Potential regulation of N-glycosylation precursor through oligosaccharide-lipid hydrolase action and glucosyltransferase-glucosidase shuttle. J Biol Chem. 1991;266:5311–5317. [PubMed]